natgillin/translations-raw huggingface dataset:
Omnitrope can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with growth disorders.
Predpisovanje in izdaja zdravila Omnitrope je le na recept, zdravljenje z njim pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z motnjami rasti.
The reference medicine for Omnitrope is Genotropin.
Referenčno zdravilo za zdravilo Omnitrope je zdravilo Genotropin.
Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin.
Zdravilo Omnitrope so proučevali, da bi dokazali, ali je primerljivo z referenčnim zdravilom Genotropin.
Omnitrope contains the active substance somatropin and is a ‘biosimilar' medicine.
Zdravilo Omnitrope vsebuje zdravilno učinkovino somatropin in je „podobno biološko zdravilo“.
The Omnitrope cartridges should only be used with the special Omnitrope injection device.
Zdravilo Omnitrope v obliki vložkov se lahko uporablja samo s posebno pripravo za injiciranje zdravila Omnitrope.
For the full list of side effects of Omnitrope, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Omnitrope, glejte navodilo za uporabo.
How is Omnitrope used?
Kako se zdravilo Omnitrope uporablja?
Growth hormone is released by the pituitary gland (a gland at the base of the brain).
Rastni hormon izloča hipofiza (žleza v možganskem dnu).
Therefore, the Agency's view was that, as for Genotropin, the benefit outweighs the identified risk and it recommended that Omnitrope be given marketing authorisation.
Zato je menila, da njegove koristi enako kot pri zdravilu Genotropin odtehtajo znana tveganja.
How does Omnitrope work?
Kako zdravilo Omnitrope deluje?
Howeve,r these antibodies do not have an effect on how well Omnitrope works.
Vendar pa ta ne vplivajo na to, kako dobro deluje zdravilo Omnitrope.
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH
100mg/cap Capsule, soft
100mg/cap kapsula, mehka peroralna uporaba
50mg/cap Capsule, soft
50mg/cap kapsula, mehka peroralna uporaba
25mg/cap Capsule, soft
25mg/cap kapsula, mehka peroralna uporaba
500mg/5ml Oral solution
500mg/5ml peroralna raztopina peroralna uporaba 100 mg/ml
21 March 2014
21. marec 2014
The Committee appointed C. Ibrahim as rapporteur and H. Jukes as co-rapporteur.
Odbor je za poročevalko imenoval C. Ibrahim, za soporočevalko pa H. Jukes.
The United Kingdom is the reference Member State and Germany and the Netherlands are concerned Member States.
Referenčna država članica je Združeno kraljestvo, zadevni državi članici pa sta Nemčija in Nizozemska.
International non-proprietary name (INN): eprinomectin
Mednarodno nelastniško ime (INN): eprinomektin
The opinion was converted into a Decision by the European Commission on 21 March 2014.
Mnenje je bilo spremenjeno v sklep Evropske komisije dne 21. marca 2014.
The decentralised procedure started on 21 February 2012.
Decentralizirani postopek se je začel 21. februarja 2012.
Written explanations were provided by the applicant on 19 November
Predlagatelj je 19. novembra 2013 podal pisna pojasnila.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the summary of product characteristics and package leaflet in Annex III.
Seznam zadevnih imen zdravila je v Prilogi I. Znanstveni zaključki so podani v Prilogi II, skupaj s povzetkom glavnih značilnosti zdravila in navodilom za uporabo v Prilogi III.
Potential serious risks were identified during the decentralised procedure by Germany regarding the environmental safety of the product.
Med decentraliziranim postopkom je Nemčija ugotovila možnost resnega tveganja, povezanega z varnostjo zdravila za okolje.
Day 60 of the CMD(v) procedure was on 18 April 2013, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP.
Šestdeseti dan postopka skupine CMD(v) je bil 18. april 2013 in ker zadevne države članice niso uspele doseči soglasja v zvezi z zdravilom, je bil postopek napoten na odbor CVMP.
On 26 April 2013, the reference Member State, the United Kingdom, notified the Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Referenčna država članica, Združeno kraljestvo, je 26. aprila 2013 obvestila agencijo, da skupina CMD(v) ni dosegla soglasja v zvezi z zdravilom, in zadevo napotila na odbor CVMP, skladno s členom 33(4) Direktive 2001/82/ES.
Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle contains eprinomectin as an active substance and is intended for use in cattle as a topical application for the treatment and control of infections from gastrointestinal roundworms (adults and fourth stage larvae), lungworms (adults and fourth stage larvae), warbles (parasitic stages), mange mites, lice and horn flies.
Zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, vsebuje zdravilno učinkovino eprinomektin in je namenjeno za lokalno uporabo pri govedu za zdravljenje in nadzorovanje okužb z želodčno-črevesnimi glistami (odraslimi in ličinkami v četrti fazi razvoja), pljučnimi črvi (odraslimi in ličinkami v četrti fazi razvoja), govejimi zolji (v parazitskem stadiju), garjami, ušmi in muhami Haematobia irritans.
On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 18 February 2013.
Ker ti pomisleki na 210. dan še vedno niso bili rešeni, je bila zadeva 18. februarja 2013 v skladu s členom 33(1) Direktive 2001/82/ES napotena na Usklajevalno skupino za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v veterinarski medicini (CMD(v)).
Therefore, the Committee adopted by consensus a positive opinion on 15 January 2014 recommending the granting of the marketing authorisations for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle with amendment to the summary of product characteristics and package leaflet of the reference Member State.
Odbor je zato 15. januarja 2014 soglasno sprejel pozitivno mnenje in priporočil odobritev dovoljenja za promet z zdravilom Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, skupaj s spremembo povzetka glavnih značilnosti zdravila in navodila za uporabo referenčne države članice.
This is a ‘hybrid' application according to Article 13(3) of Directive 2001/82/EC, as amended, referring to the reference product Eprinex PourOn Solution for Beef and Dairy Cattle.
Vloga je v skladu s členom 13(3) Direktive 2001/82/ES, kakor je bila spremenjena, „hibridna vloga“, ki se nanaša na referenčno zdravilo Eprinex kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka.
Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle is positive.
Na podlagi ocene trenutno razpoložljivih podatkov je odbor CVMP menil, da je razmerje med tveganji in koristmi za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka, pozitivno.
The applicant, Norbrook Laboratories Ltd, submitted an application for a decentralised procedure for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle.
Predlagatelj, družba Norbrook Laboratories Ltd, je predložil vlogo za decentralizirani postopek za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka.
Opinion following an Article 33(4)0F referral for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle
Mnenje v zvezi z napotitvijo v skladu s členom 33(4)0F za zdravilo Norbonex 5 mg/ml kožni poliv, raztopina za govedo, namenjeno za proizvodnjo mesa in mleka EMA/128538/2014
Such data should be submitted to the Agency together with the periodic safety update reports.
Te rezultate je treba predložiti Agenciji skupaj z rednimi posodobljenimi poročili o varnosti.
It can cause:
Povzroči lahko:
Reversal should occur rapidly within 1-2 minutes.
Reverzija mora nastopiti hitro v 1-2 minutah.
• Your dog to feel cold when touched (for example the ears).
• Pes je hladen na dotik (npr. na ušesih).
MARKETING AUTHORISATION NUMBER(S) EU/2/11/127/001
ŠTEVILKA DOVOLJENJA ZA PROMET EU/2/11/127/001
3.0 to 4.2 4.3 to 6.1 6.2 to 8.0 8.1 to 9.9 10.0 to 11.7 11.8 to 13.6 13.7 to 15.5 15.6 to 17.4 17.5 to 19.3 19.4 to 21.2 21.3 to 23.1 23.2 to 25.0 25.1 to 26.9 27.0 to 28.8 28.9 to 30.6 30.7 to 32.5 32.6 to 34.4 34.5 to 36.3 36.4 to 38.2 38.3 to 40.1 40.2 to 42.0 42.1 to 43.9 44.0 to 45.8 45.9 to 47.7 47.8 to 49.6 49.7 to 51.4 51.5 to 53.3 53.4 to 55.2 55.3 to 57.0
4,3 do 6,1 6,2 do 8,0 8,1 do 9,9 10,0 do 11,7 11,8 do 13,6 13,7 do 15,5 15,6 do 17,4 17,5 do 19,3 19,4 do 21,2 21,3 do 23,1 23,2 do 25,0 25,1 do 26,9 27,0 do 28,8 28,9 do 30,6 30,7 do 32,5 32,6 do 34,4 34,5 do 36,3 36,4 do 38,2 38,3 do 40,1 40,2 do 42,0 42,1 do 43,9 44,0 do 45,8 45,9 do 47,7 47,8 do 49,6 49,7 do 51,4 51,5 do 53,3 53,4 do 55,2 55,3 do 57,0
The unbroached vial does not require any special storage conditions.
Neodprta viala ne zahteva posebnih pogojev shranjevanja.
The systemic bioavailability of the veterinary medicinal product is approximately 40%.
Sistemska biološka razpoložljivost zdravila je približno 40 %.
Your veterinarian can best describe these for you.
Najbolje jih lahko opiše vaš veterinar.
• Loss of appetite or drinking less water.
• Izgubo teka ali pitje manj vode.
For transdermal use.
Za transdermalno uporabo.
Recuvyra should only be used for dogs.
Recuvyra se sme uporabljati samo za pse.
Recuvyra like any other medicine may cause adverse reactions.
Recuvyra lahko kot vsako drugo zdravilo povzroča neželene učinke.
Bodyweight (kilograms)
Telesna teža (kilogrami)
Your dog should not be given Recuvyra if it:
Psu se ne sme dati Recuvyre, če:
It is important that both tips make direct contact with the skin.
Pomembno je, da se obe konici neposredno dotikata kože.
50 mg/ml For a full list of excipients, see section 6.1.
50 mg/ml Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Within 5 minutes, the product dries on the skin.
V 5 minutah se zdravilo na koži posuši.
Remove the plastic protective cover from the top of the glass vial.
Odstranite plastičen zaščitni pokrovček z vrha steklene viale.
Thoroughly clean any contaminated clothing before reuse.
Pred ponovno uporabo temeljito očistite vsa onesnažena oblačila.
For the attention of dog owner
Opozorilo lastniku psa
ATCvet code: QN02AB03
Oznaka ATC vet: QN02AB03
Your veterinarian received a separate information sheet (summary of product characteristics) with more details on the correct and safe administration of Recuvyra.
Vaš veterinar je prejel posebne informacijske (Povzetek glavnih značilnosti zdravila) z več podrobnostmi o pravilnem in varnem dajanju Recuvyre.
Time to 1.0 ng/ml (hrs)
Čas do 1,0 ng/ml (ure)
Shelf life after first broaching the vial: 30 days.
Rok uporabnosti po prvem odpiranju viale: 30 dni.
The pharmacokinetic profile of the veterinary medicinal product is primarily characterised by the long period of systemic absorption.
Za farmakokinetičen profil zdravila je predvsem značilno dolgo obdobje sistemske absorpcije.
This dog was treated on: Date
Ta pes je bil zdravljen: Datum ura
Your veterinarian will ensure the product is stored correctly and safely for up to 3 years, but the contents of a bottle should be used within 30 days of the first dose being withdrawn.
Veterinar bo zagotovil pravilno in varno shranjevanje zdravila do 3 leta, a po odvzemu prvega odmerka se mora vsebina stekleničke porabiti v 30 dneh.
Facilities for the maintenance of a patent airway, intermittent positive pressure ventilation (IPPV) and oxygen supplementation should be available.
Na razpolago morajo biti naprave za vzdrževanje prehodnih dihalnih poti, intermitentno ventilacijo s pozitivnim tlakom (IPPV) in preskrbo s kisikom.
• Decreased stool production and some temporary weight loss.
• Zmanjšano izločanje blata in začasno manjšo izgubo teže.
Pharmacotherapeutic group: Analgesic, opioid, phenylpiperidene derivative.
Farmakoterapevtska skupina: analgetik, opioid, derivat fenilpiperidina.
Once seated, do not remove the adaptor.
Ko adapter sedi, ga ne odstranjujte več.
Attaching the adaptor
Pritrjevanje adapterja
The safety of the veterinary medicinal product in animals less than 6 months of age has not been established.
Varnost zdravila ni ugotovljena pri živalih, starih manj od 6 mesecev.
The veterinary medicinal product should not be used in animals with systemic illness.
Zdravilo se ne sme uporabljati pri živalih s sistemsko boleznijo.
Centre the adaptor directly over the top of the vial.
Namestite adapter točno nad sredino vrha viale.
It is important that you do not allow any other dogs or pets you may have to lick or come into contact with the area between your dog's shoulder blades where your veterinarian has applied Recuvyra for at least 3 days (72 hours) following treatment, as this might cause adverse reactions in these animals.
Pomembno je, da ne dovolite, da bi drugi psi ali domače živali, ki jih morda imate, lizali ali prihajali v stik z območjem med lopaticama vašega psa, kjer je veterinar nanesel Recuvyro, najmanj 3 dni (72 ur) po dajanju, ker lahko to povzroči neželene učinke pri teh živalih.
Rarely (i.e. in 0,01 to 0,1% of treated dogs) • Dysphoria and urinary retention.
Redko (tj. od 0,01 do 0,1% zdravljenih psov • Disforija in zadrževanje urina.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http://www.ema.europa.eu/.
The ranges (90% interval) of pharmacokinetic parameters in dogs are given below:
Območja farmakokinetičnih parametrov (90 %-ni intervali) pri psih so prikazana spodaj:
Recuvyra is supplied to your veterinarian in an amber glass bottle containing 10 ml of product.
Recuvyra se dobavlja veterinarju v rjavi steklenički, ki vsebuje 10 ml izdelka.
If there is a risk of contact with the application site, suitable protective gloves must be worn.
Če obstaja nevarnost stika z mestom dajanja, je treba nositi primerne zaščitne rokavice.
Each pack is supplied with one vial adaptor, 15 syringes and 15 applicator tips, as well as 15 package leaflets for animal owners, and 1 SPC (for the veterinarian).
Vsako pakiranje vsebuje en adapterza viale, 15 brizg in 15 aplikacijskih nastavkov, 15 navodili za uporabo za lastnike živali in 1 Povzetkom glavnih značilnosti zdravila (za veterinarja).
If necessary, your veterinarian may administer treatment to your dog (for example a reversal agent called naloxone which has a very rapid effect within 1 - 2 minutes).
Če je potrebno, lahko veterinar predpiše zdravljenje psa (npr. sredstvo za reverzijo, imenovano nalokson, ki ima zelo hiter učinek v 1-2 minutah).
As a precaution, RECUVYRA should not be administered by pregnant women.
Iz previdnostnih razlogov naj Recuvyre ne dajejo nosečnice.
Tell your veterinarian if your dog is sick or was recently ill, if it has ever had breathing, heart or blood pressure problems or epilepsy, if it has ever had bowel or kidney problems or problems with its eyes, and what medicines your dog has taken, especially within the last month.
Povejte veterinarju, če je pes bolan ali je bil pred kratkim bolan, če je kdaj imel težave z dihanjem, srcem in krvnim tlakom ali epilepsijo, če je kdaj imel težave s črevesjem ali ledvicami ali težave z očmi in katera zdravila je dobival, posebno v zadnjem mesecu.
• A polycarbonate Robertsite vial adaptor (allowing needleless luer connection to the vial).
• Polikarbonaten adapter Robertsite za viale (ki omogoča brezigelni luer priključek na vialo)
Your dog will only be allowed to go home once it has recovered from its surgery, and is drinking and eating normally.
Pes bo smel iti domov, ko si bo opomogel od kirurške operacije in bo normalno pil in jedel.
• Has broken, damaged or diseased skin at the treatment site.
• Ima raztrgano, poškodovano ali bolno kožo na mestu zdravljenja.
Avoid contact with skin, as Recuvyra can be absorbed by human skin.
Izogibajte se stiku s kožo, ker človeška koža lahko absorbira Recuvyro.
Dispose of waste material in accordance with local requirements
Odlagajte odpadne snovi v skladu z lokalnimi predpisi.
Clear, colourless to light yellow solution.
Bistra brezbarvna do svetlo rumena raztopina.
Sedation may persist beyond 24 hours after application.
Sedacija lahko traja več kot 24 ur po dajanju.
Your veterinarian should not administer Recuvyra:
Veterinar ne sme dajati Recuvyre:
To address the safety concerns remaining in relation to the novel type of product, and the uncertainty about possible interactions of concomitantly used products during the operation and in the postoperative period, the marketing authorisation holder should arrange for collation and assessment of detailed data on the clinical safety of the product in a representative sample of dogs.
Za obravnavo preostalih varnostnih vprašanj, ki se nanašajo na novo vrsto zdravila in na negotovost glede možnih medsebojnih učinkov sočasno uporabljenih zdravil med operacijo in v obdobju po operaciji, mora imetnik dovoljenja za promet z zdravilom poskrbeti za zbiranje in oceno podrobnih rezultatov o klinični varnosti zdravila na reprezentativnem vzorcu psov.
At the moment of drying, approximately 2 to 5 minutes after application, fentanyl and octyl salicylate are absorbed into the stratum corneum.
V trenutku osušitve, približno 2 do 5 minut po nanosu, se fentanil in oktilsalicilat absorbirata v stratum corneum.
However, for small children (15 kg) such contact might still result in serious exposure to fentanyl.
Pri majhnih otrocih (15 kg) pa bi lahko imel takšen stik za posledico resno izpostavitev fentanilu.
• To your dog if it has already had a dose of Recuvyra within the last 7 days.
• Če je pes v zadnjih 7 dneh že dobil odmerek Recuvyre.
The effects of the concomitant use of the veterinary medicinal product and α-adrenergic agonists have not been studied.
Učinkov hkratne uporabe tega zdravila in α-adrenergičnih agonistov niso proučili.
The veterinary medicinal product has a narrow margin of safety and it is important to measure the dose accurately to avoid over-dosing.
Zdravilo za uporabo v veterinarski medicini ima ozke varnostne meje in pomembno je, da se odmerek izmeri natančno in s tem prepreči preveliko odmerjanje.
Apply up to 0.5 ml onto the skin without moving the applicator tip.
Nanesite do 0,5 ml na kožo, ne da bi prestavljali aplikacijski nastavek.
Do not use near a naked flame.
Ne uporabljajte v bližini odprtega plamena.
Mild reductions in body temperature and heart and respiratory rates for up to 3 days following use are common.
Pogosta so blaga znižanja telesne temperature in hitrosti bitja srca in dihanja do 3 dni po uporabi.
To help you remember when your dog was given Recuvyra by your veterinarian and how long you should not let children touch your dog in the place where the product was applied, your veterinarian will make a note in the spaces provided below.
Da si boste lažje zapomnili, kdaj je veterinar dal Recuvyro vašemu psu in kako dolgo ne smete dovoliti otrokom, da se ga dotikajo na mestu, kjer je zdravilo nanešeno, bo veterinar naredil zabeležke na spodaj predvidenih mestih.
Very commonly (i.e. in more than 10% of treated dogs)
Zelo pogosto (tj. pri več kot 10 % zdravljenih psov)
SMALL CHILDREN SHOULD NOT TOUCH THE DOG FOR 72 HOURS (3 days) AFTER RECUVYRA IS APPLIED TO THE DOG.
MAJHNI OTROCI SE NE SMEJO DOTIKATI PSA 72 UR (3 dni) PO DAJANJU RECUVYRE PSU.
• Lowering of heart and breathing rates.
• Znižanje hitrosti bitja srca in dihanja.
Banbury, Oxfordshire, OX16 4RS United Kingdom.
Banbury, Oxfordshire, OX16 4RS Združeno Kraljestvo
Mild side effects such as sedation, may occur after a single accidental oral administration of more than 20 µg/kg of fentanyl (0.4 µl/kg Recuvyra).
Blagi stranski učinki, kot je sedacija, se lahko pojavijo po enem nenamernem peroralnem zaužitju več kot 20 μg/kg fentanila (0,4 μl/kg Recuvyre).
The above side effects can occur up to 3 days (72 hours) after Recuvyra was given to your dog.
Zgoraj navedeni stranski učinki lahko nastopajo do 3 dni (72) ur po dajanju Recuvyre psu.
de la Industria, 30 E-28108 Alcobendas (Madrid) Tel.: +34 91 663 5000
de la Industria, 30 E-28108 Alcobendas (Madrid) Tel.: +34 91 663 5000 Spain
Higher oral doses may induce anaesthetic effects and cardiopulmonary depression.
Večji oralni odmerki lahko povzročijo anestetične učinke in kardiopulmonalno depresijo.
The veterinary medicinal product is strictly limited for use in dogs.
Uporaba zdravila je strogo omejena na pse.
• Except as a single dose at the recommended dose rate.
• Drugače kot samo v enkratnem priporočenem odmerku.
Fentanyl plasma protein binding is estimated at approximately 60% in dogs.
Ocenjujejo, da znaša pri psih vezanje fentanila na proteine v plazmi okoli 60 %.
Recuvyra should not be used if your dog is pregnant, lactating or is used for breeding, or if your dog is less than 6 months old.
Recuvyra se ne sme uporabljati, če je vaša psica breja ali v obdobju laktacije, če se žival uporablja za vzrejo ali če je vaš pes star manj kot 6 mesecev.
• Mild sedation (sleepiness) for up to 24 hours after Recuvyra has been applied by your veterinarian.
• Blago sedacijo (zaspanost) do 24 ur potem, ko je veterinar nanesel Recuvyro.
It is imperative that the veterinary medicinal product is not applied to any other site on the body than the dorsal scapular area, as absorption has been shown to vary between different locations of skin.
Nujno je, da se to zdravilo ne nanese na nobeno drugo telesno mesto kot na hrbtno skapularno območje, ker je ugotovljeno, da se absorpcija spreminja med različnimi mesti na koži.
1 vial (10 ml) 1 vial adaptor 15 syringes 15 applicator tips
1 viala (10 ml) 1 adapter za vialo 15 brizg
• Has an allergy to the active substance (fentanyl) or to any of the excipients.
• Ima alergijo na zdravilno učinkovino (fentanil) ali katero od pomožnih snovi.
Fentanyl gradually moves through the skin into your dog's bloodstream and then relieves pain.
Fentanil počasi potuje skozi kožo v krvni obtok psa in potem lajša bolečine.
Attaching adaptor (see Figure 1):
Pritrjevanje adapterja (glejte sliko 1):
The duration of action of naloxone ranges between 45 minutes and 3 hours in the dog.
Trajanje delovanja naloksona je za pse v območju med 45 minutami in 3 urami.
Gastrointestinal stasis can result in serious complications and consideration should be given to opiate reversal in case of excessive narcosis (see section 4.10).
Gastrointestinalni zastoj ima lahko za posledico resne komplikacije in razmisliti je treba o prekinitvi dajanja opiatov, če je narkoza premočna (glejte poglavje 4.10).
When using Recuvyra your veterinarian should use less anaesthetic agents and administer them only to achieve the desired effect.
Pri uporabi Recuvyre mora veterinar uporabljati manj anestetikov in jih dajati samo za doseganje želenih učinkov.
Fentanyl very commonly causes dose-dependent sedation in dogs which is associated with potential decreased food and water intake, decreased stool production and transient weight loss.
Odvisno od odmerka fentanil zelo pogosto povzroča sedacijo psov, ki je združena z možnim zmanjšanjem zauživanja hrane in vode, zmanjšanjem izločanja blata in prehodno izgubo teže.
In field trials, 2 % of dogs treated with the veterinary medicinal product required reversal of adverse opiate effects with naloxone.
Pri preskušanju na terenu je 2 % psov, zdravljenih s tem zdravilom, potrebovalo reverzijo neželenih opiatnih učinkov z naloksonom.